| Stereochemistry | ACHIRAL |
| Molecular Formula | C6H12ClN.ClH |
| Molecular Weight | 170.08 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.ClCCN1CCCC1
InChI
InChIKey=FSNGFFWICFYWQC-UHFFFAOYSA-N
InChI=1S/C6H12ClN.ClH/c7-3-6-8-4-1-2-5-8;/h1-6H2;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C6H12ClN |
| Molecular Weight | 133.619 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
1-(2-Chloroethyl)pyrrolidine is a haloalkyl substituted pyrrolidine. It is an intermediate in the synthesis of various pharmaceutical compound. For example, 1-(2-Chloroethyl)pyrrolidine is used for the synthesis of cholinesterase inhibitors and nonsteroidal selective estrogen receptor modulator nafoxidine.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|